Rapid Influenza Diagnostic Tests (RIDT) Market — By Product Type, By Technology, By Sample Type, By End Use — Global Forecast, 2025 to 2034

Rapid Influenza Diagnostic Tests Market Size

The global rapid influenza diagnostic tests market was valued at USD 1.4 billion in 2024. The market is expected to grow from USD 1.5 billion in 2025 to USD 2.3 billion in 2034, at a CAGR of 5.1%. The market for rapid influenza diagnostic tests (RIDTs) is projected to grow tremendously due to the rising seasonal flu cases, increased adoption of point-of-care testing, and innovation in diagnostic methods. Furthermore, government initiatives aimed at improving the surveillance of influenza and conducting awareness campaigns are contributing significantly in broadening the market.

The accuracy of tests has significantly improved due to new digital RIDTs with better sensitivity and specificity, making these tests essential for healthcare providers. The shift from qualitative to semi-quantitative RIDTs has also been beneficial for diagnostics. The introduction of multiplexed tests, which can detect influenza along with other respiratory pathogens, has increased the clinical utility of RIDTs. Artificial intelligence (AI) and machine learning technologies support these advancements by automating test interpretation and reducing errors. With more spending on healthcare infrastructure, these technologies are making RIDTs more widely available to a greater number of patients.
 

Governments in various countries are increasing their efforts to improve the supervision and diagnosis of influenza to reduce the burden caused by the disease. The U.S. CDC's Influenza Division International Program and The World Health Organization's Global Influenza Surveillance and Response System have highlighted the importance of accurate diagnosis in the early stages of the disease. Agencies like the FDA or EMA are supporting seasonal diagnosis by fast-tracking the approval of RIDTs. A growing number of public health systems are receiving grants and subsidies for diagnostic testing, which drives rapid influenza diagnostic tests market growth. These grants help improve public health systems and increase patient awareness about the importance of timely treatment and diagnosis through a multi-channel marketing approaches. These regulations also foster early treatment and diagnosis through marketing campaigns that enhance public awareness about such issues.
 

Rapid influenza diagnostic tests (RIDTs) are immunoassays that identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and display the results in a qualitative manner. RIDTs can provide results in less than 15 minutes. However, RIDTs have limited sensitivity in detecting influenza viruses in respiratory specimens compared to RT-PCR or viral culture. Therefore, confirmation tests are required for false-negative RIDT results, especially during the peak influenza season.
 

Rapid Influenza Diagnostic Tests Market Trends

• New technologies, changing consumer demands, and a transformation in the delivery of healthcare services are some of the factors fueling the growth of the RIDT market. One notable trend is the integration of artificial intelligence into diagnostic platforms. AI-powered RIDTs improve accuracy, minimize false positives and negatives, and enhance the efficiency of the diagnostic process in both clinical and point-of-care settings. Significant progress have been made in this area, particularly during flu season, to ensure that individuals are accurately diagnosed and treated in a timely manner.
   
• In addition, market growth is also expected to increase during the forecast period due to the rising popularity of home-testing kits. With the surge in telehealth services combined with the ease of self-testing, patients are able to self-test for influenza, get immediate results, and consult with healthcare professionals through video calls. This change is significantly more noticeable since the COVID-19 pandemic, as there is a greater emphasis on accessing healthcare services in a quick and efficient manner.
   
• Due to the improved sensitivity and specificity of molecular diagnostic RIDTs, they are gaining more acceptance compared to traditional ones. Advanced tests, such as those using nucleic acid amplification (NAA) testing, are ideal for identifying influenza strains with low viral loads.
   
• The evolution of markets is being driven by the increased availability of multiplex diagnostic tools. With these methods, patients can detect influenza A and B simultaneously with other viral respiratory infections like RSV and SARS-CoV-2. This helps provide a greater overall diagnostic solution while eliminating the need to take multiple tests.
   
• Many experts are looking for ways to create biodegradable testing parts and reduce the overall waste from test packages. This effort aims to address broader environmental issues. Along with government programs that encourage more frequent use of influenza diagnostics, this is expected to help the market grow further.
   

Rapid Influenza Diagnostic Tests Market Analysis

In 2021, the global market was valued at USD 1 billion. The following year, it saw a slight increase to USD 1.1 billion, and by 2023, the market further climbed to USD 1.2 billion.
 

Based on product type, the rapid influenza diagnostic tests market is segmented as conventional RIDTs and digital RIDTs. The conventional RIDTs segment generated revenue of USD 822.9 million in 2024.
 

• Conventional RIDTs are popular in the market because they are affordable and easy to find. These tests are simple to produce and do not need much infrastructure, making them a suitable for areas with limited resources. Their low cost is especially helpful in public health campaigns in developing countries, where tight budgets often restrict access to healthcare.
   
• Additionally, conventional RIDTs are easy to use and don’t require specialized training, which makes them ideal for places like clinics, schools, and workplaces. Their fast results help healthcare providers make quick decisions, which is especially important during busy flu seasons. This simplicity has made them a key tool in managing seasonal flu outbreaks.
   

Based on technology, the rapid influenza diagnostic tests market is segmented into immunochromatographic assays, lateral flow assays, PCR, and other technologies. The immunochromatographic assays segment is expected to drive business growth and expand at a CAGR of 5.9%, reaching over USD 1.3 billion by 2034.
 

• Immunochromatographic assays are expected to hold substantial market share due to their excellent sensitivity and specificity. These tests can identify even small amounts of the virus, ensuring accurate results. This is especially important for detecting infections early in high-risk groups like children and the elderly, helping to prevent serious complications.
   
• These assays are also becoming more common in decentralized testing locations, such as pharmacies and urgent care centers. Their small size and minimal equipment requiements make them a practical option for these settings. Additionally, advancements in technology have made these tests faster and more reliable, and hence healthcare providers increasingly prefer them.
   

Based on sample type, the rapid influenza diagnostic tests market is segmented into nasal swab, throat swab, and other samples. The nasal swab segment is expected to drive business growth and expand at a CAGR of 5.9%, reaching over USD 1.2 billion by 2034.
 

• The segment is controlled by the nasal swab region as it is simple to use and provides accurate results. Swabs cause low tissue irritation, making them suitable for both children and adults. Obat is in commonly used in clinics for influenza cases, which also helps grow the market.
   
• Nasal swabs are multi-functional as they fit regular and molecular RIDTs. They are optimal for early diagnosis of influenza because they capture high viral loads. Providers equally benefit from nasal swabs because of their reliable performance in point-of-care and laboratory test systems
   

Based on end use, the rapid influenza diagnostic tests market is segmented as diagnostic centers, hospitals, research laboratories, and other end users. The diagnostics centers segment dominated the market with a revenue share of 41.3% in 2024.
 

• Diagnostic centers are the top end-users in the RIDT market because they have advanced facilities and skilled staff. These centers use state-of-the-art technology to deliver accurate and efficient testing. Patients often choose diagnostic centers for reliable results, especially for molecular RIDTs that require specialized equipment.
   
• There is also a growing demand for comprehensive testing, including multiplex diagnostics, which has increased the use of RIDTs in diagnostic centers. These centers offer a variety of testing options, helping healthcare providers distinguish between influenza and other respiratory illnesses. Their involvement in large-scale influenza monitoring programs further strengthens their leading role in the market.
   

In 2024, the North America region accounted for the largest share of 34.5% in the global rapid influenza diagnostic tests market. The region's strong market share can be attributed to its well-established healthcare infrastructure, easy availability of rapid test kits, and increasing adoption of point of care testing.
 

The U.S. rapid influenza diagnostic tests market was valued at USD 331 million in 2021.  The country dominated the North American market in 2023 with USD 401.3 million growing from USD 365.8 million in 2022.
 

• The U.S. dominates North America's RIDT market due to strong healthcare policies, high disease awareness, and significant investment in diagnostic tools. Programs like Vaccines for Children (VFC) help provide flu diagnostics and vaccinations to underserved populations. The increased use of RIDTs at retail pharmacies such as CVS and Walgreens, along with telehealth services, has made influenza testing more accessible for many people.
   
• Government programs like the National Influenza Pandemic Strategy have also supported these RIDT initiatives. To satisfy the growing demand, large companies like Roche Diagnostics and Quidel have moved their operations to the U.S. Additionally, there is a growing trend of integrating RIDTs into corporate wellness programs, encouraging their use in office environments.
   

UK rapid influenza diagnostic tests market is projected to grow remarkably in the coming years in European market.
 

• The RIDT market in the UK is still developing, driven by improvements in flu control from the National Health Service (NHS) and the growing demand during peak seasons. The NHS has included RIDTs in its system's response to influenza by providing rapid diagnostic services in primary care, hospitals, and pharmacies. The growing acceptance of point-of-care testing has made RIDTs an important part of Britain's integrated healthcare system.
   
• The general increase in public awareness of the need for early intervention for flu has impacted the demand for RIDTs in the UK. Companies like Abbott and Sekisui Diagnostics play a significant role in this market with their RIDTs manufactured to NHS specifications. Other diagnostic and academic institutions also collaborate to support the development and adoption of innovative diagnostic solutions. Additionally, the government's strong focus on reducing hospital admissions and avoiding complications due to flu has increased the need for effective and reliable diagnostic devices.
   

China holds a dominant position in the Asia Pacific rapid influenza diagnostic tests market.
 

• China has a strong competitive advantage in the Asia Pacific region in the influenza diagnostic tests industry.
   
• To support public health development and early illness diagnosis, the Chinese Government is making large investments, which are driving the rapid growth of the RIDT market. The 2030 China Health program promotes early diagnosis and illness management, leading to increased use of RIDTs by hospitals, outpatient clinics, and community health centers. The government's focus on monitoring infectious diseases has strengthened campaigns against influenza, especially in rural and underserved areas.
   
• At the same time, more local manufacturers in China are producing RIDTs at affordable prices. Local suppliers of diagnostic tools, such as Beijing Wantai Biological Pharmacy and Guangzhou Wondfo Biotech, offer cost-effective yet high-quality diagnostic products. The growing number of private diagnostic clinics and retail pharmacies in urban areas has also contributed to market expansion. Additionally, collaborations with global suppliers have introduced advanced molecular RIDTs to tertiary care hospitals, further boosting the market.
   

Rapid Influenza Diagnostic Tests Market Share

Quidel Corporation, Abbott Laboratories, and Roche Diagnostics are at the top of the RIDT market because they are multinational companies with a broad range of product portfolios, extensive networks, strong brand names, and effective distribution channels. These companies hold the largest share of XX% of the global market in 2024. All of these players are investing heavily in R&D to address the challenges of traditional diagnostic devices and to improve the sensitivity and specificity of RIDTs. Additionally, the introduction of innovative molecular diagnostic RIDTs has changed the marketplace, especially in developed countries with high healthcare spending. Companies, including Beijing Wantai Biological Pharmacy and Guangzhou Wondfo Biotech, are expanding their product offerings and increasing the availability of flu diagnostic tests in rural areas. This expansion is driving the growth of diagnostics in these regions. The competition in this region is leading to technological advancements and lower prices, making cost-effective RIDTs more accessible worldwide.
 

This shift comes from strategically forming partnerships between private sector diagnostic companies and public health organizations. Specifically, partnerships with the CDC and WHO for influenza monitoring and surveillance have increased the use of rapid influenza diagnostic tests (RIDT), especially during flu peak seasons and global pandemics. Additionally, strategic mergers and acquisitions, such as DiaSorin's purchase of Luminex Corporation, have improved the molecular diagnostic capabilities of these companies and strengthened their positions in the rapid influenza diagnostic tests market.
 

The basic structure of the healthcare delivery system is shifting towards more decentralized models that support home sampling and other point-of-care diagnostic services. Companies worldwide are using new technologies, such as artificial intelligence-powered diagnostic devices and multiplex testing, to meet these needs. The combination of public health awareness and ongoing innovation is expected to drive the rapid influenza diagnostic tests market in the coming years.
 

Abbott is a household name for its broad array of rapid diagnostic tests, especially the Abbott BinaxNOW influenza test. This test is simple to perform, and the results are accurate within 15 minutes with no special device or training needed. Abbott's solutions provide instant aid to healthcare practitioners by diagnosing influenza in a timely manner, which ensures better quality care. Abbott has strong image and distribution in various countries, which makes the tests easily accessible in rural and underprivileged regions. The company also considers affordability, allowing its solutions to be used in most healthcare environments.
 

BD has developed the Veritor System for the Rapid Detection of Influenza A & B, with results available in 10 minutes. Its primary advantage comes from its high sensitivity and differentiation of influenza A from B. BD is well known for its dependable and good quality testing instruments for clinical laboratories and point-of-care facilities. With increased use of automation and simpler workflows, BD has increased healthcare convenience while decreasing the waiting times for diagnosis, which is vital during flu season.
 

DiaSorin is a company that is well known in the field of molecular diagnostics due to the high sensitivity of their tests that detect genetic material of the influenza virus. Their LIAISON MDX system is an all-in-one unit, fully automated and giving results of very good quality within 40 minutes. DiaSorin uses real-time PCR technology to bolster the accuracy in testing for influenza, further minimizing false positive or negative cases. These molecular RIDTs are designed for large volume usage, but DiaSorin has had great success with them in hospitals and reference laboratories as a more reliable substitute for antigen tests.
 

Rapid Influenza Diagnostic Tests Market Companies

Prominent players operating in the rapid influenza diagnostic tests (RIDT) industry include:

• 3B BlackBio
• Abbott
• Access Bio
• BD
• bioMérieux
• CHEMBIO
• DiaSorin
• Meridian
• Quidel Corporation
• Roche
• SEKISUI
• Siemens HEALTHINEERS
• Thermo Fisher
   

Rapid Influenza Diagnostic Tests Industry News

• In October 2024, the FDA approved the Healgen Rapid Check COVID-19/Flu A&B Antigen Test for marketing. This at-home test, which uses a nasal swab, can detect both COVID-19 and influenza A & B. It’s available without a prescription and delivers results in just 15 minutes. This is the first over-the-counter flu test to receive marketing authorization outside of emergency use. This approval expands at-home testing options, which is especially important as respiratory illnesses like flu and COVID-19 remain a concern.
   
• In March 2024, Co-Diagnostics, Inc.'s joint venture, CoSara, received approval from Indian regulators for its Influenza Multiplex PCR Test. This test can detect multiple influenza strains at the same time, making it a more efficient diagnostic tool for healthcare providers. This approval is a significant step toward improving access to advanced diagnostic testing in India.
   
• In June 2024, the NIH, through its RADx Tech Independent Test Assessment Program (ITAP), worked with diagnostic manufacturers to speed up the review and approval of multiplex tests that detect both COVID-19 and flu A/B. This effort aims to increase the availability of rapid, point-of-care (POC), and at-home tests, which are essential for quick diagnosis and treatment.
   
• In May 2024, Watmind USA received FDA Emergency Use Authorization (EUA) for its SpeedySwab 15-Minute At-Home 3-in-1 Antigen Test. This test can identify COVID-19, Influenza A, and Influenza B. Developed in collaboration with NIH’s RADx ITAP, it provides a fast, easy-to-use, and affordable solution for individuals aged 2 and older to check their symptoms at home. Using Lateral Flow Assay (LFA) technology, the test delivers quick results, helping users distinguish between these viruses, which often have overlapping symptoms.
   

The rapid influenza diagnostic tests market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 — 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Conventional RIDTs
• Digital RIDTs

Market, By Technology

• Immunochromatographic assays
• Lateral flow assays
• PCR
• Other technologies

Market, By Sample Type

• Nasal swab
• Throat swab
• Other sample types

Market, By End Use

• Diagnostic centers
• Hospitals
• Research laboratories
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE